Replies to post #214041 on Biotech Values

[dangerM]

in addition to that you should also read more on the study itself (one of the first links of a google search shows
https://www.dddmag.com/article/2016/04/new-focus-il-12-oncology-research )

as well as look at the competition, both from a scientific standpoint as well as on their financing structure (in case one or two might look more interesting)

TLR 7/9
http://www.dynavax.com <- well, according to a reuters article they will either have outlicensed their HCB vaccine soon or need some kind of (probably?) debt financing to commercialize it & finance their IO-program
http://checkmatepharma.com <- private company
http://www.iderapharma.com <- have not checked financing structure yet
http://www.mologen.com <- personally, I really do not like their financing structure

(certainly not a complete list, but these should be the more known ones)

IL12
http://celsion.com <- have not checked financing structure yet
http://www.inovio.com/products/cancer-vaccines/hpv/cervical-cancer/ <- have not checked financing structure yet
http://oncosec.com <- somewhat ok, but looks to me as if they will need a financing round within a year
http://neumedicines.com <- private company

(it's quite surprising how many trials with IL12 for cancer but also other indications are recruiting ... so this is not a complete list)

many, many more approaches to make cold tumors hot
https://www.noxxon.com <- personally, I really do not like their financing structure
...
...